Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.91 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.91 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting resilience amid market challenges. They emphasized a commitment to innovation.
We are pleased with our performance this quarter despite the ongoing challenges.
Our focus remains on innovation and meeting customer needs.
The earnings report shows that Zoetis Inc exceeded EPS expectations, which is a positive sign for the company's profitability. However, the stock reacted negatively, declining by 0.23%. This could indicate that investors were looking for more comprehensive revenue details or future guidance, which were not provided.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRUPO AEROMEXICO S A ADR
Feb 16, 2021